Rasagiline is an anti-Parkinson's agent and MAO inhibitor which can enhance the activity of dopamine. It is used for initial monotherapy or as adjunct to levodopa in the treatment of idiopathic Parkinson's disease.
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Treat Parkinson's | 401 |
|
|
|
|
|
111 |
| Other | 31 |
|
|
|
|
|
13 |
| Stiffness/Spasticity | 18 |
|
|
|
5 | ||
| Support another treatment | 13 |
|
|
5 | |||
| disease-related symptoms | 3 | 0 | |||||
| Mobility | 3 |
|
1 |
See all 505 patients currently taking Rasagiline
Mouse over the table for more information
Top 10 dosages based on patients currently taking Rasagiline. See all 11 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Side effects too severe
|
38 | 42% |
|
|
Did not seem to work
|
36 | 40% |
|
|
Doctor's advice
|
22 | 24% |
|
|
Other
|
14 | 16% |
|
|
Expense
|
8 | 9% |
|
|
Personal research
|
7 | 8% |
|
|
Not indicated
|
1 | 1% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on November 21, 2009.